GEN Exclusives

More »

Company Updates

More »
Oct 1, 2010 (Vol. 30, No. 17)

Expediting RNA Delivery with Small Parcels

Nanosized Particles Use Molecular Motor from Bacteriophage to Slip Into Cells and Drop Off Cargo

  • Click Image To Enlarge +
    Potential use of phi29 pRNA trimers as polyvalent delivery vectors: Three positions are available to carry specific therapeutic, targeting, and diagnostic payloads.

    The U.S. PTO recently granted a patent for a new RNA interference nanotechnology, called packaging RNA or pRNA, to Kylin Therapeutics. The company, founded in 2007, is developing the pRNA platform to deliver RNA-based nanoparticles to silence genes that cause disease. “Our intellectual property is unique in the field of small RNA interference,” says Eric Davis, president, CEO, and co-founder of the company.

    Peixuan Guo, Ph.D., invented the pRNA nanotechnology while he was a professor of molecular virology and biomedical engineering at Purdue University. Dr. Guo, a co-founder of Kylin, now directs the Nanomedicine Bionanotechnology Center at the University of Cincinnati.

    The pRNA technology was modeled on the design of a molecular motor found in the phi29 bacteriophage. Individual subunits of pure RNA that self-assemble into dimers, trimers, and hexamers make up pRNA. A single pRNA dimer is about 25 nanometers. Promising RNA therapeutics such as aptamers, ribozymes, and therapeutic RNAs can be incorporated into individual subunits of pRNA.

    RNA interference is a natural gene-silencing process within all cells. The pRNA method exploits this process by selectively turning off genes responsible for cancer, infectious diseases, and other illnesses. To deliver RNA-based therapeutics specifically to diseased cells, targeting molecules are incorporated into individual pRNA subunits. These targeting agents include small molecules such as folate, peptides, aptamers, or monoclonal antibodies that insure that pRNA is taken up by diseased cells. Once the nanoparticles enter diseased cells, Dicer enzymes cleave and release the therapeutic RNAs, thereby turning off genes that cause the disease.

    Both the targeting molecules and gene-silencing agents are tailored to match specific disease tissue. In pRNA hexamers, for example, six positions are available to carry molecules for cell recognition, therapy, and detection.

    In addition to RNA therapeutics, other materials, including fluorescent beads, radioisotopes, or quantum dots, can be attached to detect cancer at different stages or treat it, according to Davis. The platform has broad potential to combine multiple RNA functions into one nanoparticle, such as receptor antagonism/activation, cell targeting/delivery, and gene knockdown through RNA interference mechanisms.

  • Supporting Evidence

    Dr. Guo discovered that the structural and molecular features of phi29 allow it to be easily manipulated to form gene-targeting delivery vehicles. In a study reported in the September 2005 issue of Human Gene Therapy, Dr. Guo and co-workers constructed pRNA dimers containing either a receptor-binding RNA aptamer or folate for cell recognition. The other subunit carried small interfering RNAs, ribozymes, or other chemical groups. The dimers were successfully delivered to specific cells and silenced the genes for green fluorescent protein, luciferase, survivin, and BCL-2 in a variety of cancer cells.

    The pRNA complexes also could target and treat chronic viral infections such as HIV and hepatitis. In a proof-of-concept study, the pRNA method strongly inhibited replication of coxsackievirus, a common pathogen involved in myocarditis.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?